Werewolf Therapeutics, Inc.

NasdaqGS:HOWL Voorraadrapport

Marktkapitalisatie: US$88.3m

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Werewolf Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

De winst van Werewolf Therapeutics zal naar verwachting dalen met 23.6% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 38.1% per jaar. De winst per aandeel zal naar verwachting afnemen met 7.1% per jaar.

Belangrijke informatie

-23.6%

Groei van de winst

-7.1%

Groei van de winst per aandeel

Biotechs winstgroei28.6%
Inkomstengroei38.1%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Good

Laatst bijgewerkt19 Aug 2024

Recente toekomstige groei-updates

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 13
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Recent updates

Is Werewolf Therapeutics (NASDAQ:HOWL) Using Debt Sensibly?

Jul 31
Is Werewolf Therapeutics (NASDAQ:HOWL) Using Debt Sensibly?

Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1

Jul 01

Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding

Jun 04
Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding

Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space

Apr 04

Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Feb 07
Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?

Jan 19
Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?

There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise

Dec 09
There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise

Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates

Sep 30
Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 13
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

May 06
We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Jan 27
Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate

Oct 24
We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate

We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Jul 08
We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Mar 24
Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Dec 09
Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Winst- en omzetgroeiprognoses

NasdaqGS:HOWL - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202610-137-54N/A5
12/31/202510-102-47N/A6
12/31/20243-74-67N/A6
6/30/20249-54-42-41N/A
3/31/202416-42-39-38N/A
12/31/202320-37-33-33N/A
9/30/202326-37-41-40N/A
6/30/202325-41-50-47N/A
3/31/202321-50-40-37N/A
12/31/202216-54-44-41N/A
9/30/20229-60-45-41N/A
6/30/20224-62-41-39N/A
3/31/2022N/A-115-50-50N/A
12/31/2021N/A-202-43-43N/A
9/30/2021N/A-205-36-36N/A
6/30/2021N/A-197-29-29N/A
3/31/2021N/A-127-23-23N/A
12/31/2020N/A-28-19-19N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat HOWL de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat HOWL de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat HOWL de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van HOWL ( 38.1% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van HOWL ( 38.1% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van HOWL naar verwachting over 3 jaar hoog zal zijn


Ontdek groeibedrijven